Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
| Metric | Value as of 30 September 2011 |
|---|---|
| Issued Ordinary Shares (25p each) | 5,569,988,261 |
| Treasury Shares | 505,396,816 |
| Total Voting Rights | 5,064,591,445 |
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period regarding financial performance or capital structure.
Guidance, Outlook, and Risks
The filing text does not provide clear values or commentary regarding guidance, outlook, risks, contingencies, or unusual items. The document is a statutory notification of share counts for shareholder disclosure calculations.
Important Facts for Investors to Verify
- Verify the total number of voting rights (5,064,591,445) to determine notification thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (505,396,816) when calculating outstanding share counts.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.